drugset / Trial / NCT00838396
A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of the study is to evaluate the efficacy and safety of arbaclofen placarbil (XP19986) compared to placebo in patients with gastroesophageal reflux disease.
Timeline
- Start
- 2005-10
- Primary completion
- 2006-08
- Completion
- 2006-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Arbaclofen Placarbil | Small molecule | 10 mg | — |
| Subject | Arbaclofen Placarbil | Small molecule | 20 mg | — |
| Subject | Arbaclofen Placarbil | Small molecule | 40 mg | — |
| Subject | Arbaclofen Placarbil | Small molecule | 60 mg | — |